Integrating venetoclax-based targeted and/or immune therapies for chronic lymphocytic leukemia - PubMed
5 hours ago
- #chemotherapy-free
- #chronic lymphocytic leukemia
- #targeted therapy
- Venetoclax (VEN) is a selective BCL-2 inhibitor and a key treatment for chronic lymphocytic leukemia (CLL).
- VEN-based combinations offer deep remissions and chemotherapy-free, fixed-duration treatment options.
- Clinical trials show high response rates, durable progression-free survival, and undetectable minimal residual disease (MRD) with VEN combinations.
- Combinations with anti-CD20 antibodies, BTK inhibitors, bispecific antibodies, and CAR T-cells are discussed.
- Fixed-duration VEN-obinutuzumab/rituximab regimens outperform chemoimmunotherapy.
- MRD-guided strategies are explored, but their superiority over fixed-duration approaches is unproven.
- Emerging data on retreatment, sequencing strategies, dose optimization, and next-gen BTKi are highlighted.
- Future studies are needed to compare regimens and optimize MRD-driven decision-making.